Losartan (Cozaar) is an angiotensin II receptor blocker (ARB) used to treat hypertension, protect the kidneys in patients with type 2 diabetes and nephropathy, reduce cardiovascular mortality in heart failure, and prevent stroke in hypertensive patients with left ventricular hypertrophy. It works by blocking AT1 receptors, preventing angiotensin II from causing vasoconstriction and aldosterone release. Common side effects include dizziness, elevated potassium, and mild creatinine rise. Unlike ACE inhibitors, losartan does not cause a dry cough; it carries a black box warning for fetal toxicity and must be discontinued immediately when pregnancy is detected.
Losartan
Uses & FDA Indications
Losartan was the first angiotensin II receptor blocker (ARB) approved in the United States and remains one of the most prescribed agents in its class. It offers similar cardiovascular protection to ACE inhibitors but without the hallmark dry cough, making it an important alternative for patients who cannot tolerate ACE inhibitor therapy.
Hypertension
Losartan is FDA-approved for treatment of hypertension in adults and children aged 6 and older. It lowers blood pressure through sustained blockade of angiotensin II's vasoconstrictive effects and aldosterone release.
Diabetic Nephropathy
The RENAAL trial demonstrated that losartan significantly reduces the progression of kidney disease in patients with type 2 diabetes and nephropathy, decreasing the risk of end-stage renal disease (dialysis), doubling of serum creatinine, and death. This makes it a preferred antihypertensive in this population regardless of blood pressure status.
Heart Failure (Stroke Volume Preservation)
Losartan is approved to reduce cardiovascular mortality in patients with heart failure who cannot tolerate ACE inhibitors. The ELITE II trial compared losartan to captopril in this setting.
Stroke Prevention
The LIFE trial showed that losartan was superior to atenolol in reducing fatal and nonfatal stroke in hypertensive patients with left ventricular hypertrophy — an effect beyond simple blood pressure lowering.
How It Works
Losartan is a competitive antagonist at the angiotensin II type 1 (AT1) receptor. Angiotensin II is a potent vasoconstrictor produced via the renin-angiotensin-aldosterone system (RAAS). When the kidneys detect low blood pressure or reduced sodium, they release renin, which triggers a cascade producing angiotensin II. By blocking AT1 receptors, losartan prevents angiotensin II from causing vasoconstriction, aldosterone secretion (sodium and water retention), and cardiac and vascular remodeling.
Unlike ACE inhibitors, ARBs like losartan do not prevent the breakdown of bradykinin — the accumulation of which is responsible for the persistent dry cough seen in up to 20% of ACE inhibitor users. This makes ARBs the preferred alternative in cough-intolerant patients while providing equivalent blood pressure lowering and organ protection.
Losartan is a prodrug that undergoes first-pass hepatic metabolism (via CYP2C9 and CYP3A4) to its active carboxylic acid metabolite, E-3174, which is approximately 10–40 times more potent than the parent compound at the AT1 receptor and has a longer half-life — contributing importantly to the drug's therapeutic effect.
Side Effects
Common
- Dizziness or lightheadedness, especially with the first dose or in volume-depleted patients
- Hyperkalemia (elevated potassium) — due to reduced aldosterone activity
- Elevated serum creatinine — modest rise in creatinine expected and generally acceptable; signals intended hemodynamic effect
- Fatigue
- Upper respiratory infection symptoms
- Back pain
Less Common but Notable
- Angioedema — rare but potentially life-threatening; less common than with ACE inhibitors, but cross-reactivity possible in ACE inhibitor-induced angioedema
- Hypotension, especially in volume-depleted or heart failure patients
- Renal impairment worsening in patients with bilateral renal artery stenosis
- Transient elevation in liver enzymes
Drug Interactions
| Drug / Class | Interaction | Clinical Significance |
|---|---|---|
| ACE inhibitors (e.g., lisinopril) | Dual RAAS blockade increases risk of hypotension, hyperkalemia, and acute kidney injury without additional cardiovascular benefit | High — combination generally contraindicated |
| Aliskiren (renin inhibitor) | Triple RAAS blockade causes significant risk of hypotension, hyperkalemia, and renal failure | High — contraindicated in patients with diabetes or renal impairment |
| Potassium-sparing diuretics / potassium supplements | Additive hyperkalemia risk; losartan reduces aldosterone-mediated potassium excretion | Moderate-High — monitor potassium; avoid combination when possible |
| NSAIDs | Reduce antihypertensive efficacy; increase risk of acute kidney injury through additive effects on renal perfusion | Moderate — avoid chronic NSAID use; use acetaminophen instead when possible |
| Fluconazole (CYP2C9 inhibitor) | Inhibits losartan conversion to active metabolite E-3174, potentially reducing efficacy | Moderate — monitor blood pressure; may need dose adjustment |
| Lithium | Losartan reduces renal lithium clearance, increasing lithium levels and toxicity risk | Moderate — monitor lithium levels frequently when initiating or changing losartan |
Warnings & Contraindications
⚠ BLACK BOX WARNING: Losartan can cause fetal harm and death when used during the second and third trimesters of pregnancy. Drugs acting directly on the RAAS have caused oligohydramnios, fetal limb contractures, craniofacial deformation, hypoplastic lung development, and neonatal death. Discontinue losartan as soon as pregnancy is detected.
Renal Artery Stenosis
Bilateral renal artery stenosis (or unilateral stenosis in a solitary functioning kidney) is a relative contraindication. Losartan-mediated reduction in efferent arteriolar tone can cause precipitous drops in GFR and acute kidney injury in these patients.
Hyperkalemia Risk
Patients with diabetes, chronic kidney disease, or those on potassium-sparing agents are at highest risk for dangerous hyperkalemia. Baseline and periodic monitoring of serum potassium and creatinine is essential, especially when starting therapy or adjusting the dose.
Volume Depletion
Patients who are volume-depleted (from diuretics, dietary sodium restriction, dialysis, or vomiting/diarrhea) are at increased risk of symptomatic hypotension with the first dose. Correcting volume status before initiating therapy is advisable.
Frequently Asked Questions
Is losartan the same as lisinopril?
Both lower blood pressure through the renin-angiotensin system, but they work at different points in the cascade. Lisinopril is an ACE inhibitor that prevents the formation of angiotensin II, while losartan is an ARB that blocks angiotensin II's receptor. The key practical difference is that lisinopril frequently causes a persistent dry cough (in 10–20% of users) due to bradykinin accumulation, while losartan does not. Both provide similar blood pressure control and kidney protection in diabetic nephropathy.
Can losartan harm my kidneys?
A modest, reversible rise in creatinine (typically 10–30%) is expected and acceptable when starting losartan — it reflects the intended hemodynamic effect on the kidneys, not damage. Losartan actually slows the long-term progression of kidney disease in patients with diabetic nephropathy. However, in patients with bilateral renal artery stenosis, severe dehydration, or those taking NSAIDs concurrently, acute kidney injury can occur. Periodic monitoring is standard practice.
Why does my doctor check my potassium while I take losartan?
Losartan reduces aldosterone levels, which normally promote potassium excretion in the kidney. The result is a tendency toward potassium retention (hyperkalemia). In most patients this is mild and asymptomatic, but elevated potassium can cause dangerous heart rhythm disturbances. Patients with kidney disease, diabetes, or those on potassium supplements are at greatest risk and require more frequent monitoring.
Check for interactions with losartan.
Check Drug Interactions →